M Ventures and Novartis Venture Fund co-led a round for the oncology drug startup that also featured fellow corporate venturing unit Pfizer Ventures.
Switzerland-based cancer drug developer FoRx Therapeutics completed a $10m seed round yesterday that was co-led by M Ventures and Novartis Venture Fund, subsidiaries of pharmaceutical firms Merck Group and Novartis.
Investment firm Omega Funds co-led the round with the corporates. Pharmaceutical company Pfizer participated through its Pfizer Ventures unit and the round was filled out by venture capital firm Life Sciences Partners.
Founded in autumn 2019 and utilising University of Geneva research, FoRx is developing cancer therapies intended to spare…
